Cargando…

Circulating Tumor Cells as an Indicator of Treatment Options for Hepatocellular Carcinoma Less Than or Equal to 3 cm in Size: A Multi-Center, Retrospective Study

BACKGROUND: The status of circulating tumor cells (CTCs) is related to the recurrence of hepatocellular carcinoma (HCC), which is also one of the reasons for the poor prognosis of HCC. The purpose of this study was to explore whether CTCs can help guide the choice of treatment methods for HCC. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qiao, Xia, Feng, Gao, Hengyi, Wu, Zhenheng, Cao, Wenjing, Xiang, Qingfeng, Guan, Zhifeng, Su, Yang, Zhang, Weiqiao, Chen, Weiqiang, Mo, Ali, Li, Shuqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251203/
https://www.ncbi.nlm.nih.gov/pubmed/35795230
http://dx.doi.org/10.3389/fsurg.2022.895426
_version_ 1784739986033082368
author Zhang, Qiao
Xia, Feng
Gao, Hengyi
Wu, Zhenheng
Cao, Wenjing
Xiang, Qingfeng
Guan, Zhifeng
Su, Yang
Zhang, Weiqiao
Chen, Weiqiang
Mo, Ali
Li, Shuqun
author_facet Zhang, Qiao
Xia, Feng
Gao, Hengyi
Wu, Zhenheng
Cao, Wenjing
Xiang, Qingfeng
Guan, Zhifeng
Su, Yang
Zhang, Weiqiao
Chen, Weiqiang
Mo, Ali
Li, Shuqun
author_sort Zhang, Qiao
collection PubMed
description BACKGROUND: The status of circulating tumor cells (CTCs) is related to the recurrence of hepatocellular carcinoma (HCC), which is also one of the reasons for the poor prognosis of HCC. The purpose of this study was to explore whether CTCs can help guide the choice of treatment methods for HCC. METHODS: This study is a multicenter retrospective study, including 602 patients with HCC. CTCs were detected in the overall cohort before operation. There were 361 patients in the training cohort and 241 patients in the validation cohort. Patients were divided into CTC-negative group (CTCs = 0/5 mL) and the CTC-positive group (CTCs ≥ 1/5 mL) according to CTCs status. Subgroup analysis was performed according to CTCs status. We compared overall survival, and recurrence outcomes for HCC patients with different CTC statuses after undergoing radiofrequency ablation (RFA) or surgical resection (SR) RESULTS: There was no significant difference in overall survival (OS) and recurrence-free survival (RFS) between the RFA group and SR group for CTC-negative patients in both the training cohort and the validation cohort (P > 0.05). However, among CTC-positive patients, the clinical outcome of patients in the SR group was significantly better than those in the RFA group. CTC-positive patients who underwent RFA had increased early recurrence compared to those who underwent SR. RFA is an independent risk factor for survival and recurrence in CTC-positive HCC patients CONCLUSIONS: The CTC status could serve as an indicator to guide the choice between surgical resection or radiofrequency ablation for early hepatocellular carcinoma. Surgical resection is recommended for CTC-positive patients.
format Online
Article
Text
id pubmed-9251203
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92512032022-07-05 Circulating Tumor Cells as an Indicator of Treatment Options for Hepatocellular Carcinoma Less Than or Equal to 3 cm in Size: A Multi-Center, Retrospective Study Zhang, Qiao Xia, Feng Gao, Hengyi Wu, Zhenheng Cao, Wenjing Xiang, Qingfeng Guan, Zhifeng Su, Yang Zhang, Weiqiao Chen, Weiqiang Mo, Ali Li, Shuqun Front Surg Surgery BACKGROUND: The status of circulating tumor cells (CTCs) is related to the recurrence of hepatocellular carcinoma (HCC), which is also one of the reasons for the poor prognosis of HCC. The purpose of this study was to explore whether CTCs can help guide the choice of treatment methods for HCC. METHODS: This study is a multicenter retrospective study, including 602 patients with HCC. CTCs were detected in the overall cohort before operation. There were 361 patients in the training cohort and 241 patients in the validation cohort. Patients were divided into CTC-negative group (CTCs = 0/5 mL) and the CTC-positive group (CTCs ≥ 1/5 mL) according to CTCs status. Subgroup analysis was performed according to CTCs status. We compared overall survival, and recurrence outcomes for HCC patients with different CTC statuses after undergoing radiofrequency ablation (RFA) or surgical resection (SR) RESULTS: There was no significant difference in overall survival (OS) and recurrence-free survival (RFS) between the RFA group and SR group for CTC-negative patients in both the training cohort and the validation cohort (P > 0.05). However, among CTC-positive patients, the clinical outcome of patients in the SR group was significantly better than those in the RFA group. CTC-positive patients who underwent RFA had increased early recurrence compared to those who underwent SR. RFA is an independent risk factor for survival and recurrence in CTC-positive HCC patients CONCLUSIONS: The CTC status could serve as an indicator to guide the choice between surgical resection or radiofrequency ablation for early hepatocellular carcinoma. Surgical resection is recommended for CTC-positive patients. Frontiers Media S.A. 2022-06-20 /pmc/articles/PMC9251203/ /pubmed/35795230 http://dx.doi.org/10.3389/fsurg.2022.895426 Text en Copyright © 2022 Zhang, Xia, Gao, Wu, Cao, Xiang, Guan, Su, Zhang, Chen, Mo and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Surgery
Zhang, Qiao
Xia, Feng
Gao, Hengyi
Wu, Zhenheng
Cao, Wenjing
Xiang, Qingfeng
Guan, Zhifeng
Su, Yang
Zhang, Weiqiao
Chen, Weiqiang
Mo, Ali
Li, Shuqun
Circulating Tumor Cells as an Indicator of Treatment Options for Hepatocellular Carcinoma Less Than or Equal to 3 cm in Size: A Multi-Center, Retrospective Study
title Circulating Tumor Cells as an Indicator of Treatment Options for Hepatocellular Carcinoma Less Than or Equal to 3 cm in Size: A Multi-Center, Retrospective Study
title_full Circulating Tumor Cells as an Indicator of Treatment Options for Hepatocellular Carcinoma Less Than or Equal to 3 cm in Size: A Multi-Center, Retrospective Study
title_fullStr Circulating Tumor Cells as an Indicator of Treatment Options for Hepatocellular Carcinoma Less Than or Equal to 3 cm in Size: A Multi-Center, Retrospective Study
title_full_unstemmed Circulating Tumor Cells as an Indicator of Treatment Options for Hepatocellular Carcinoma Less Than or Equal to 3 cm in Size: A Multi-Center, Retrospective Study
title_short Circulating Tumor Cells as an Indicator of Treatment Options for Hepatocellular Carcinoma Less Than or Equal to 3 cm in Size: A Multi-Center, Retrospective Study
title_sort circulating tumor cells as an indicator of treatment options for hepatocellular carcinoma less than or equal to 3 cm in size: a multi-center, retrospective study
topic Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251203/
https://www.ncbi.nlm.nih.gov/pubmed/35795230
http://dx.doi.org/10.3389/fsurg.2022.895426
work_keys_str_mv AT zhangqiao circulatingtumorcellsasanindicatoroftreatmentoptionsforhepatocellularcarcinomalessthanorequalto3cminsizeamulticenterretrospectivestudy
AT xiafeng circulatingtumorcellsasanindicatoroftreatmentoptionsforhepatocellularcarcinomalessthanorequalto3cminsizeamulticenterretrospectivestudy
AT gaohengyi circulatingtumorcellsasanindicatoroftreatmentoptionsforhepatocellularcarcinomalessthanorequalto3cminsizeamulticenterretrospectivestudy
AT wuzhenheng circulatingtumorcellsasanindicatoroftreatmentoptionsforhepatocellularcarcinomalessthanorequalto3cminsizeamulticenterretrospectivestudy
AT caowenjing circulatingtumorcellsasanindicatoroftreatmentoptionsforhepatocellularcarcinomalessthanorequalto3cminsizeamulticenterretrospectivestudy
AT xiangqingfeng circulatingtumorcellsasanindicatoroftreatmentoptionsforhepatocellularcarcinomalessthanorequalto3cminsizeamulticenterretrospectivestudy
AT guanzhifeng circulatingtumorcellsasanindicatoroftreatmentoptionsforhepatocellularcarcinomalessthanorequalto3cminsizeamulticenterretrospectivestudy
AT suyang circulatingtumorcellsasanindicatoroftreatmentoptionsforhepatocellularcarcinomalessthanorequalto3cminsizeamulticenterretrospectivestudy
AT zhangweiqiao circulatingtumorcellsasanindicatoroftreatmentoptionsforhepatocellularcarcinomalessthanorequalto3cminsizeamulticenterretrospectivestudy
AT chenweiqiang circulatingtumorcellsasanindicatoroftreatmentoptionsforhepatocellularcarcinomalessthanorequalto3cminsizeamulticenterretrospectivestudy
AT moali circulatingtumorcellsasanindicatoroftreatmentoptionsforhepatocellularcarcinomalessthanorequalto3cminsizeamulticenterretrospectivestudy
AT lishuqun circulatingtumorcellsasanindicatoroftreatmentoptionsforhepatocellularcarcinomalessthanorequalto3cminsizeamulticenterretrospectivestudy